HideChilds = False
SystemName =
 

Bioverativ is a global biotechnology company dedicated to transforming the lives of people living with hemophilia and other blood disorders.

History of commitment to patients and science

Our History

At Bioverativ, a Sanofi company, we are proud to carry forward a rich heritage of making a meaningful difference in the haemophilia community. 

We aim to honour our history of innovation by relentlessly pursuing the discovery and development of new medicines to address areas of serious need for people with haemophilia, sickle cell disease and other rare blood disorders.

The diagram below includes products not registered in Australia.

Where We Came From

2018

Bioverativ acquired by Sanofi

First patient dosed in Phase 3 study of sutimlimab (formerly BIVV009) for treatment of cold agglutinin disease

2017

FDA accepts Investigational New Drug application for ST-400

a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia developed as part of a collaboration between Bioverativ and Sangamo Therapeutics.

Bioverativ and Bicycle Therapeutics

enter into strategic research collaboration to develop therapies for haemophilia and sickle cell disease.

Bioverativ and Invicro form novel, advanced imaging collaboration

focused on improving management of joint health in people with haemophilia.

Bioverativ acquires True North Therapeutics

a privately-held, clinical-stage rare disease biotechnology company and strengthens pipeline with a first-in-class monoclonal antibody in development to treat cold agglutinin disease.

FDA accepts Investigational New Drug application for BIVV001

a novel, investigational factor VIII therapy designed to potentially extend protection from bleeds with prophylaxis dosing of once weekly or longer for people with haemophilia A.

Bioverativ is launched as an independent, publicly-traded, global biopharmaceutical company

focused transforming the lives of people with haemophilia, sickle cell disease and other rare blood disorders.

2016

Biogen announces a planned spin-off of its haemophilia business

to form a separate company focused on the discovery, research, development and commercialisation of therapies for haemophilia.

2014

ALPROLIX ® is approved for treatment of haemophilia B in the United States, Australia, Canada and Japan.

Biogen and Swedish Orphan Biovitrum (Sobi) announce pledge to donate up to 1 billion IUs of clotting factor to countries in the developing world.

ELOCTATE ® is approved for treatment of haemophilia A in the United States, Australia, Canada and Japan.

2012

Biogen, in collaboration with the American Thrombosis and Hemostasis Network,

the National Hemophilia Foundation, and Bloodworks Northwest, launches free genetic testing for people with haemophilia A and B in the United States through My Life, Our Future campaign. The program is later expanded to include potential and confirmed carriers of the disorder.

2010

Biogen is the first to launch CoRes to support the community

2007

Biogen acquires Syntonix Pharmaceuticals

2003

Syntonix focuses on extended half-life haemophilia treatments.

1998

Syntonix Pharmaceuticals is founded, based on Harvard and Brandeis research.

1978

Biogen is founded by a group of accomplished scientists

to establish a new pharmaceutical company with an emphasis on breakthroughs in biology.